Nadia Harbeck, MD, PhD: Expert Perspective on De-escalating Breast Cancer Therapy With Paclitaxel, Pertuzumab, and Trastuzumab

Posted: Tuesday, June 15, 2021

Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses the clinical implications of treating patients who have early breast cancer with a de-escalated regimen of neoadjuvant paclitaxel plus pertuzumab and trastuzumab.